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CSCs are responsible for the high rate of recurrence and chemoresistance of different
types of cancer. The current antineoplastic agents able to inhibit bulk replicating cancer
cells and radiation treatment are not efficacious toward CSCs since this subpopulation has
several intrinsic mechanisms of resistance. Among these mechanisms, the expression of
ATP-Binding Cassette (ABC) transporters family and the activation of different signaling
pathways (such as Wnt/β-catenin signaling, Hedgehog, Notch, Akt/PKB) are reported.
Therefore, considering ABC transporters expression on CSCs membranes, compounds
able to modulate MDR could induce cytotoxicity in these cells disclosing an exciting
and alternative strategy for targeting CSCs in tumor therapy. The next challenge in the
cure of cancer relapse may be a multimodal strategy, an approach where specific CSCs
targeting drugs exert simultaneously the ability to circumvent tumor drug resistance
(ABC transporters modulation) and cytotoxic activity toward CSCs and the corresponding
differentiated tumor cells. The efficacy of suggested multimodal strategy could be
probed by using several scaffolds active toward MDR pumps on CSCs isolated by tumor
specimens.
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INTRODUCTION
The emerging concept about tumorigenesis is that cancer lesions
are organized in a hierarchy of heterogeneous cell populations
displaying different biological properties and tumorigenic poten-
tials (Lorico and Rappa, 2011). Among these populations, only
a small portion, the cancer stem cell or tumor-initiating cell
(CSC/TIC) subpopulation is able to induce tumor formation and
growth, leading to differentiated cells, the bulk of the tumor.
In 1977 Hamburger and Salmon suggested the “CSC theory” by
hypothesizing that cancer originates fromuncommon cells, CSCs,
showing pluripotency and self-renewal (Hamburger and Salmon,
1977; Boman and Wicha, 2008). In 1997 Lapidot and coworkers
identified CSCs in leukemia on the basis of cell-surface-markers
expression (Lapidot et al., 1994). The discovery of CSCs in
leukemia and in several solid tumors, such as breast carcinoma
(Al-Hajj et al., 2003; Hemmati et al., 2003; Singh et al., 2003; Carla
et al., 2005; Fang et al., 2005; Xin et al., 2005; Lawson et al., 2007;
Li et al., 2007; Ricci-Vitiani et al., 2007), was the proof of the CSC
theory in cancer development.
CSC/TICs are characterized by the following properties: (a)
production of all types of cells in a tumor, including CSC/TICs
and non-CSC/TICs; (b) unlimited self-renewal and division
capacity; (c) quiescence or slow proliferation, and (d) resistance
to conventional antineoplastic therapy (Clevers, 2011). Moreover,
recent studies have demonstrated that CSC/TIC phenotypes such
as self-renewal and pluripotency are acquired by the activation of
oncogenic genes or the inactivation of tumor suppressor genes
(Baccelli and Trumpp, 2012). Since CSCs are characterized by
specific surface markers, this subpopulation of cells can be iso-
lated from mixed tumorigenic and non-tumorigenic tumor cells,
by different methods of immune selection. CD44 targeting is used
in the treatment of acute myeloid leukemia (AML) (Jin et al.,
2006), CD24 targeting is for the treatment of colon and pancreatic
cancer (Sagiv et al., 2008) and CD133 is targeted for the treat-
ment of hepatocellular and gastric cancer (Smith et al., 2008). The
current antineoplastic agents, able to inhibit bulk replicating can-
cer cells, and radiation treatment are not efficacious toward CSCs
and, therefore, targeting these cells could be an helpful strategy
for eradicating tumors more efficiently.
However, CSCs possess several intrinsic mechanisms of
resistance to current chemotherapeutic drugs. Among these
mechanisms, the expression of ATP-Binding Cassette (ABC)
transporters family (An andOngkeko, 2009; Calcagno et al., 2010;
Fuchs et al., 2010; Clevers, 2011; Moitra et al., 2011; Pietras,
2011) and the activation of different signaling pathways such as
Wnt/β-catenin signaling (Teng et al., 2010; Yeung et al., 2010;
Takebe et al., 2011; Janikowa and Skarda, 2012), Hedgehog (Hh),
Notch (Kobune et al., 2009; Wang et al., 2009; Zhao et al., 2009;
Takebe et al., 2011; Janikowa and Skarda, 2012; Jiang et al., 2012),
Akt/PKB, ATR/CHK1 survival pathways (Ma et al., 2008; Korkaya
et al., 2009; Jiang et al., 2012) and constitutive activation of NF-κB
are reported (Zhou et al., 2008; Liu et al., 2010).
The first of these mechanisms is the overexpression of
ABC transporters such as P-glycoprotein (P-gp), Breast Cancer
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Resistance Protein (BCRP), and Multidrug Resistance-associated
Proteins (MRPs) that use the energy of ATP hydrolysis to extrude
compounds out of cells (Colabufo et al., 2010). These pro-
teins are overexpressed in several tumors and, since responsible
for drug efflux, are the main cause of MultiDrug Resistance
(MDR) (Colabufo et al., 2010). Among these transporters, P-gp
is the mostly studied and is localized in the luminal mem-
brane of endothelial cells constituting the Blood-Brain Barrier
(BBB), Blood-CerebroSpinal Fluid Barrier (B-CSF), and Blood-
Testis Barrier (BTB); thus P-gp exerts a protective function in our
body (Pharm et al., 2008; Colabufo et al., 2010). BCRP as P-gp
monomer, is considered a “half-transporter” and it effluxes the
same P-gp substrates (Pharm et al., 2008; Colabufo et al., 2010).
MRPs differ from P-gp for the presence of an additional and spe-
cific five transmembrane domain and it efflux organic ions with
high molecular weight (Pharm et al., 2008; Colabufo et al., 2010).
Since several antineoplastic drugs are substrates of ABC trans-
porters, one of the strategy to reverse MDR is the use of inhibitors
toward these pumps and their co-administration with antineo-
plastic agents (Perez-Tomas, 2006; Teodori et al., 2006; Gimenez-
Bonafe et al., 2008). However, when antineoplastic drugs and
P-gp inhibitors are co-administrated, an increased toxicity has
been observed because, at the same time, the protective role of
P-gp is abolished (Coley, 2010).
Over the last decade, our research group has developed P-gp
ligands with different scaffolds displaying different P-gp intrin-
sic activities (Colabufo et al., 2008a,b, 2009, 2013; Contino et al.,
2012, 2013a,b; Nesi et al., 2014). Therefore, considering ABC
transporters expression on CSCs membranes, compounds able to
modulate MDR activity could induce cytotoxicity in these cells
disclosing an exciting and alternative strategy for targeting CSCs
in tumors therapy.
CSCs BIOMARKERS
CSCs display several cell surface markers and their detection is
useful for the identification of CSCs in tumors. In addition, the
development of antibodies or antibody constructs toward these
markers is also suggested as a therapeutic strategy to target CSCs
(Kwon and Shin, 2013).
CD133 AND ALDH1
CD133 and ALDH1 have been identified as markers of TICs in
primary human ovarian tumors (Landen et al., 2010). CD133
has been also identified as surface marker to characterize adult
stem/progenitor cells in human thyroid glands (Thomas et al.,
2006). ALDH1 and CD133 are also markers for the identifica-
tion of CSCs in colorectal carcinoma (CRC) (Zhou et al., 2014).
CD133, together with CD44, is a specific cell-surface marker of
prostate cancer (Wang et al., 2013a).
CD44, CD117, CD24
The hyaluronic acid (HA) receptor CD44 and the stem cell
factor receptor CD117 are specific surface markers of ovarian
CSC/TICs (Zhang et al., 2008). CD44+CD117+ cells isolated
from human ovarian adenocarcinomas represent a subpopulation
with an ovarian tumor-initiating capacity, that, injected in mice,
induce original tumors from which they are derived (Zhang et al.,
2008). CD24+ cells, isolated from patient tumor specimens, are
enriched in ovarian CSC/TICs and have stem-like properties, such
as chemoresistance, self-renewal and differentiation (Gao et al.,
2010).
METHODS FOR THE ISOLATION OF CSCs
Fluorescence-Activated Cell Sorting (FACS) is amagnetic cell sep-
aration method used to isolate CSCs based on the expression of
specific cell surface markers, such as CD24, CD44, and CD133
(Wright et al., 2008; Takaishi et al., 2009). The detection can be
performedwith specific antibodies in flow cytometry, competitive
ELISA (cELISA) or magnetic beads (Dobbin and Landen, 2013).
Xia and coworkers have developed humanized antibodies toward
the surface marker CD133 that was detected by cELISA (Xia et al.,
2013). However the limitation of surface markers recognition is
that the results can be ascribed to the specific studied population.
Therefore, a second method, represented by the detection of the
activity of a specific protein such as the membrane pump ABCG2
or ALDH1A1 enzyme, seems to be more useful than markers
recognition alone. The first technique uses the DNA-binding
dye Hoechst 33342, originally developed for bone marrow cells
(Goodell et al., 1996). This fluorescent dye, used to identify a
Hoechst-negative CSC “side population” (Kondo et al., 2004), has
been successfully employed to isolate stem cells from solid tissues
such as skeletal muscle, lung, liver, testis, kidney, skin, mammary
gland and brain (Challen and Little, 2006). This method allows
to select the cells displaying an increase in the Hoechst 33342
efflux, ABCG2-mediated, from the nucleus. The limitation of this
method is due to the dye toxicity (Siemann and Keng, 1986; Erba
et al., 1988).
The high ALDH activity described for CSCs suggested also
this enzyme as a probe to isolate these cells. Aldefluor, an
ALDH1 substrate, initially used for the isolation of hematopoi-
etic stem cells by FACS (Storms et al., 1999; Cheung et al.,
2007) and for CSCs separation in tumor tissue and cancer
cell lines (Moreb, 2008; Jiang et al., 2009), has been success-
fully used for ALDH1 activity detection of CSCs in lung (Jiang
et al., 2009), prostate (Li et al., 2010), breast (Charafe-Jauffret
et al., 2010), colon (Huang et al., 2009a), and bladder (Su
et al., 2010). Aldefluor contains the ALDH1 substrate BODIPY-
aminoacetaldehyde (BAAA), that is converted into the fluorescent
metabolite BODIPY-aminoacetate (BAA) by ALDH1 (Storms
et al., 1999). BAA is then retained in living cells, because of
its charge and also because Aldefluor inhibits the multidrug-
resistance transporters. Therefore, Aldefluor-treated cells, with
high ALDH1 activity, display high fluorescence and can be iso-
lated by FACS into two subpopulations: ALDH-hi and ALDH-
low (Moreb, 2008). This method has been validated for some
cancers but it has not been widely employed because of some
limitations due to cells handling that can induce stress, disrupt
gene expression, and lead to altered cell physiology (Orfao and
Ruiz-Arguelles, 1996). To overcome these limitations, the use of
Adelfluor staining has been assessed in adherent cell cultures, that
resulted in the attached-cell Aldefluor method (ACAM). ACAM
displays several advantages since single-cell imaging of physio-
logical processes in CSCs is easier in monolayers than in cells
suspension or tumorsphere cultures that are usually used for
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growing CSCs (Fael Al-Mayhani et al., 2009; Pollard et al., 2009;
Hirschhaeuser et al., 2010).
CSCs have also been usually sorted into SP cells using UV exci-
tation (λ = 350 nm) but the limitation of this method was the
cell damage caused by UV radiation exposure. Tomiyasu et al.
reported a new method in which CSCs have been sorted by a vio-
let laser (λ = 407 nm) to avoid DNA damage (Tomiyasu et al.,
2014).
Another method to select CSCs is the use of molecular probes,
termed aptamers, that are produced by the iterative in vitro
selection process SELEX (Systematic Evolution of Ligands by
EXponential enrichment) (Ellington and Szostak, 1990; Tuerk
and Gold, 1990). Aptamers are short single-stranded oligonu-
cleotides of DNA or RNA sequences that fold into unique sec-
ondary and tertiary structures that selectively bind the target
proteins and other small molecules with high affinity and selectiv-
ity. They can be synthesized in vitro and therefore do not require
animal or bacterial hosts for production. In recent years, in order
to improve aptamers qualities and reducing time and cost of pro-
duction, a number of new SELEX variants have been performed
and among them, cell-SELEX uses whole living cells as target to
select DNA aptamers (Shangguan et al., 2006; Sefah et al., 2010).
Aptamers have many appealing features: low molecular weight,
easy chemical modifications, low toxicity and immunogenicity,
long shelf-life, high affinity (Kd value is in the picomolar to
nanomolar range) and high specificity. They can be used in diag-
nosis, for purification processes, in drug discovery and in therapy
(Proske et al., 2005). In particular, the therapeutic perspectives
involve the targeting of chemotherapeutic agents, nanoparticles,
drug-encapsulated liposomes and radioactive materials on cell
specific biomarkers. Aptamers bind their targets with high affin-
ity and specificity discriminating very closely related targets.
The anti-theophylline aptamer is able to distinguish theophylline
from caffeine, and the anti L-arginine RNA aptamer binds more
strongly L-arginine than D-arginine (Jenison et al., 1994; Geiger
et al., 1996). Aptamers are also useful in drug delivery strat-
egy: 2′-fluoro- RNA aptamers have effect toward the highly
expressed prostate specific membrane antigene (PSMA) (Lupold
et al., 2002) and Docetaxel-encapsulated nanoparticles function-
alized with a specific aptamer (A10) target PSMA expressing
cells (Farokhzad et al., 2006). Another interesting example is
AS1411 aptamer that recognizes Nucleolin (NCL), a multifacto-
rial protein involved in many cellular pathways of cancer. AS1411
has been functionalized with cisplatin-liposome and evaluated
in MCF-7 (NCL positive) and LNCaP (NCL negative) cell lines.
The cytotoxic effects were higher in MCF-7 cells as compared to
LNCaP cells (Cao et al., 2009). Moreover, specific aptamers are
used in several assays to isolate, enrich and identify CSCs and for
the characterization of specificmarkers for CSCs such as aptamers
toward HA domain of CD4, RNA aptamers targeting CD133, a
cell surface glycoprotein considered a universal marker of nor-
mal hematopoietic and organ-specific stem cells and aptamers
identifying brain CSCs (Griguer et al., 2008; Kim et al., 2013).
STRATEGIES TO ERADICATE CSCs
CSCs are responsible for tumor re-growth and potentially resis-
tant to antitumor therapies. Therefore, the development of
FIGURE 1 | Cancer stem cells targeting strategies.
strategies that can act effectively against this subpopulation of
cells has been envisaged, such as (Figure 1):
– Immunological therapies;
– Evaluation of genes and pathways pivotal in CSCs regulation;
– High-throughput screening (HTS) of potential inhibitory
compounds;
– Regulation of tumor microenvironment.
IMMUNOLOGICAL THERAPIES
Since current cancer therapies fail to eradicate CSCs, causing can-
cer recurrence and progression, the use of monoclonal antibodies
(mAbs) and antibody constructs selective for CSCs is a novel can-
cer therapeutic strategy. Several studies have been performed on
cell surface markers that are associated with CSCs. These markers
have been suggested as targets for antibodies, for antibody-drug
conjugates (ADCs) in immunological therapies to overcome the
side effects and the limitations of current cancer chemotherapies
(Naujokat, 2014). Several mAbs, directed toward specific surface
markers (Anti-CD123, Anti-CD44, Anti-CD47, Anti-CD133) or
toward protein of CSCs (Anti-Notch1 and Anti-Frizzled) have
been reported (Naujokat, 2014). Antibody constructs can be
classified as bispecific antibodies (BsAb), targeting two different
surface markers (such as BsAb-CD123 and -CD3) or as trispe-
cific antibodies when they target three different markers (such
as CD123, CD33, CD16) (Naujokat, 2014). The use of mAbs or
mAbs constructs had high efficacy in tumor xenografts mice and
in some clinical trials and since these markers or proteins are
expressed in CSCs, they can be specifically targeted by mAbs or
constructs without collateral tissue damage. Moreover, it is also
possible to conjugate antineoplastic drugs to mAbs leading to
ADCs. As example, Lou et al. have developed a dual-targeting
drug delivery system displaying an outer layer of polymers and
traditional anti-cancer drugs such as doxorubicin dispersed in the
polymer (Lou et al., 2012). The internal part is represented by the
ADCs since includesmAbs directed to the specificmarker of CSCs
(such as anti-CD133mAb or anti-CD44mAb), highly cytotoxic
drugs (such as calicheamicin) and linkers. The inner ADCs can
be released from the delivery system in tumor cells where CSCs
are recognized by the specific mAb of the system and ADCs are
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endocytosed. Some ADCs have displayed good antitumor effects
and have entered preclinical trials (Iyer and Kadambi, 2011).
PhotoChemical Internalization (PCI) is a another innova-
tive drug delivery technology based on light-controlled cytosolic
release of drugs entrapped in endosomes or lysosomes (Stratford
et al., 2013).
The combination of CD133-targeting therapeutics with PCI
technology, where light-activation is constrained to the tumor,
has been performed to develop an immunotoxin consisting of a
biotinylated anti-CD133mAb bound to streptavidin-saporin sys-
tem (Stratford et al., 2013). This combined strategy has been
used in a sarcoma model system (harboring CSCs within the
CD133 high population) and the results have demonstrated that
PCI-based drug delivery by the CD133-receptor inhibited cells
viability and growth, and the ability to form tumors in vivo. Since
CD133 overexpression is also found in different tumors, the study
performed on sarcoma model can be transferable to treatment of
all solid tumors expressing CD133 (Smith et al., 2008; Waldron
et al., 2011; Bostad et al., 2013).
REGULATING PATHWAYS
The inhibition of biological pathways crucial in the regulation of
the renew and the maintenance of CSCs, in combination with tra-
ditional chemotherapies, is a promising strategy for the treatment
of CSCs and to circumvent MDR.
Notch pathway
The Notch pathway is important in gene regulation and in cell
differentiation processes. This pathway is involved in the patho-
genesis of several human tumors such as ovarian cancer (Park
et al., 2006). There are four members of the mammalian Notch
receptor family (Notch 1–4) activated through a series of cleav-
age events. The mature Notch receptors are composed of two
subunits generated from an initial cleavage event by furin-like
convertase. Blaumueller et al. (1997) Notch signaling pathway
activation occurs when a Notch receptor binds to ligands. This
binding causes a receptor conformational change allowing a sec-
ond cleavage by tumor necrosis-factor-alpha converting enzyme
(TACE) (Brou et al., 2000). The following cleavage is carried out
by preselenin (a γ -secretase) releasing Notch intracellular domain
and activating target genes expression. Notch plays a significant
role in ovarian CSCs regulation and in platinum resistance (Park
et al., 2006; Takebe et al., 2011). Also, Notch 3 inhibitors increase
the sensitivity of ovarian cancer to cisplatin, reducing the ovarian
CSC population (McAuliffe et al., 2012).
Wnt pathway
The Wnt signaling pathway, regulating several processes funda-
mental in embryogenesis such as proliferation, differentiation,
polarity, adhesion and motility, plays key roles in tumorige-
nesis. Indeed, the progression of several cancers is associated
with specific mutations in Wnt pathway components resulting
in dysregulated β-catenin-mediated gene transcription. There
are two distinct pathways for transduction of Wnt signals: the
“canonical” Wnt/β-catenin pathway and the “non-canonical” β-
catenin-independent pathway (Clevers and Nusse, 2012). The
“canonical” pathway is activated by several Wnt ligands through
the binding to Frizzled (FZD) receptors and to low-density
lipoprotein receptor-related proteins-5/6 (LRP5/6) co-receptors.
As a result, β-catenin accumulates in the cytoplasm, translo-
cates to the nucleus and regulates transcription of Wnt/β-catenin
target genes by binding to the T-cell factor/lymphoid enhancer
factor (TCF/LEF) (MacDonald et al., 2009). In the absence ofWnt
signaling, β-catenin levels are regulated by a cytoplasmic destruc-
tion complex (DC). DC is a multiproteins complex composed
of protein Axin, the tumor suppressor adenomatous polyposis
coli protein (APC), casein kinase α (CK1α), glycogen synthase
kinase 3 β (GSK3) and additional associated proteins such as the
members of the PARP-family of poly-ADP-ribosylation enzymes
(Tankyrases, TNKSs). Axin, the concentration-limiting compo-
nent of DC, is pivotal for the stability of the β-catenin-DC. By
destabilizing Axin, TNKSs directly control the levels of this pro-
tein. Therefore, TNKSs inhibition, promoting Axin stabilization,
leads to β-catenin phosphorylation and degradation, attenuat-
ing Wnt signaling (Liu et al., 2002; Lee et al., 2003). For this
reason, in recent years, considerable efforts have been made to
identify drugs that inhibit Wnt/β-catenin signaling. Another fac-
tor exerting a fundamental role in the biogenesis of Wnt pathway
is represented by a member of the Membrane-Bound O-Acyl
Transferase (MBOAT) family, Porcupine (PORCN) (Tanaka et al.,
2000). PORCN is an integral membrane enzyme resident in the
endoplasmic reticulum, required for the lipid modification of
Wnt proteins. Acylation by PORCN is essential for the proper
secretion and activity of Wnt signaling and, therefore, its inhibi-
tion is an attractive therapeutic strategy in diseases with increased
Wnt signaling (Chen et al., 2009).
Hedgehog pathway
The Hh pathway is involved in several developmental processes of
cells: determination of cell fate, patterning, proliferation, survival,
and differentiation (Varjosalo and Taipale, 2008). In mammals,
three Hh proteins (Sonic Hh, Indian Hh, and Desert Hh) are
derived from proteolysis of inactive precursor that contains its
own autoprocessing domain. Hh acts by binding to 12 transmem-
brane glycoprotein components Patched (Ptch). In the absence of
ligand, Ptch constitutively represses the activity of Smoothened
(Smo), a 7-pass transmembrane spanning protein with homol-
ogy to G-protein coupled receptors. When Hh ligand binds to
Ptch, the repression of Smo is released and the expression and/or
post-translational processing of the three GLI zinc-finger tran-
scription factors, inducing the expression of several target genes,
is modulated (Sasaki et al., 1999). Overactivation of Hh path-
way is associated with cancer and emerging data from many
human tumors, including glioblastoma, breast cancer, pancre-
atic cancer, and chronic myeloid leukemia (CML), have suggested
that Hh signaling regulates CSCs (Liu et al., 2006; Bar et al.,
2007; Feldmann et al., 2007; Zhao et al., 2009). The Hh signaling
pathway interacts also with other pathways commonly activated
in human cancers, such as the phosphatidylinositol-3-kinase
(PI3K)/Akt pathway (Riobo et al., 2006).
PI3K/AKT pathway
PI3K/AKT is important for pluripotency maintenance of stem
cells. PI3K enzymes are normally regulated by growth factors
Frontiers in Pharmacology | Pharmacology of Anti-Cancer Drugs July 2014 | Volume 5 | Article 163 | 4
Zinzi et al. Tumor stem cells eradication
and are useful to phosphorylate phospholipids on the plasma
membrane (Hennessy et al., 2005). In addition, it has been sug-
gested that PI3K/Akt activation pathway is required for CSCs
maintenance and viability in breast cancer, prostate cancer, and
brain tumor (Zhou et al., 2007; Hambardzumyan et al., 2008;
Dubrovska et al., 2009). The PI3K/Akt pathway can also modu-
late functions of ABC transporters through various mechanisms.
Inhibition of the PI3K/Akt pathway causes BCRP internalization
in hematopoietic stem cells and glioma stem-like cells. Hence, the
PI3K/Akt pathway can be an attractive target for cancer therapy
(Mogi et al., 2003; Bleau et al., 2009).
HIGH-THROUGHPUT SCREENING (HTS)
The development of agents active toward CSCs population may
be useful in the treatment of patients with recurrent cancer.
HTS allows to identify potential compounds targeting specifi-
cally CSCs. In recent years, several studies have been carried out
and in one of these studies the chemical library Microsource
Spectrum collection of 2000 compounds has been screened to
identify therapeutic agents inhibiting Glioblastome Multiforme
stem cells (GSCs). This library has been selected based on the
structural and biological diversity and consisted of FDA approved
drugs, compounds in the late-phase clinical trials, experimental
drugs and natural products. Among these, Disulfiram, a clinically
approved drug for the treatment of alcoholism, was identified as a
potent inhibitor ofmultiple patient-derived GSCs (Germain et al.,
2013).
Another study has been carried out in order to identify agents
able to selectively inhibit a cell-line model of breast CSCs screen-
ing over 300,000 compounds of the Molecular Libraries Small
Molecules Repository (MLSMR) from the National Institute of
Health (NIH). Among these compounds, a cinnamide analog
displayed 20-fold selective inhibition of the breast CSC-line cell
(HMLE_sh_Ecad) over the control (HMLE_sh_eGFP) (Hothi
et al., 2012).
In another study, HTS of 825 potential drugs (the National
Cancer Institute’s “Mechanistic Set” library) toward ovarian
CSCs and the subsequent identification of compounds displaying
potential activity as ovarian CSC therapeutic agents is reported.
Several compounds were classified as inhibitors and, among these,
5 compounds FDA-approved (dactinomycin, plicamycin, vinblas-
tine, vincristine, and mepacrine) were identified as anticancer
drugs (Mezencev et al., 2012).
TUMOR MICROENVIRONMENT
It has been proposed that CSCs are maintained by their surround-
ing microenvironment called “niche.” Niche, important for CSCs
sustaining, is composed by immune and stromal cells, blood ves-
sels and extracellular matrix components. Biological processes,
such as inflammation, hypoxia and angiogenesis, are important
for CSCs, and signaling from this microenvironment is crucial
for the activation of pathways involved in the maintenance of
TICs functions (Cabarcas et al., 2011; Hanahan and Weinberg,
2011). Tumor hypoxia is implicated in the development of resis-
tance to many conventional chemotherapeutic agents. It induces
a decreased sensitivity to apoptotic and other cell-death signals,
and increased signaling promoting angiogenesis, proliferation
Chart 1 | Natural HIF inhibitors.
and systemic metastasis capacity (Feldmann, 2001; Kunz and
Ibrahim, 2003). The initial response of cancer cells to hypoxia is
the activation of hypoxia responsive transcription factors (HIFs)
that regulate a number of genes involved in glucose metabolism,
cell survival, erythropoiesis, stem cell maintenance, angiogenesis
and resistance to chemotherapy and radiotherapy (Majmundar
et al., 2010). Molecules like langkamide, piplartine and 3,4,5-
trimethoxycinnamic acid (Chart 1), displaying HIF-2 inhibitory
activity, may be used for targeting HIFs mediated regulation of
CSCs (Bokesch et al., 2011). Another important transcription fac-
tor, involved in tumor growth, progression, and in the resistance
to chemotherapy, is NFkB: this factor and HIF1α together reg-
ulate transcription of thousand genes controlling vital cellular
processes (Gupta et al., 2010).
MOLECULES ACTIVE TOWARD CSCs
PORCUPINE AND TANKSs INHIBITORS
In the last years, considerable efforts have been made to identify
drugs able to inhibit Wnt/β-catenin signaling, either by block-
ing Wnt secretion (PORCN inhibitors) or by interfering with
β-catenin, by binding its transcription factor targets (TANKSs
inhibitors).
Starting from four IWP ligands, additional PORCN inhibitors
have been identified, that are characterized by two structural
motifs of IWPs (phthalazinone and pyrimidinonemoieties) inter-
acting with PORCN and important for the activity. The lead
optimization step led to a significant improvement in activity and
to the identification of IWP-L6 (Chart 2) as a new sub-nanomolar
PORCN inhibitor (Chen et al., 2009;Wang et al., 2013b). The first
TANKSs inhibitor, identified by Huang et al. through a chemical
genetic screen, was XAV-939 (Chart 2) (Huang et al., 2009b). It
selectively affects β-catenin-mediated transcription, by stimulat-
ing its degradation by stabilizing Axin. By HTS, JW55, IWR-1,
and WIKI4 (Chart 2) as specific tankyrases inhibitors have been
discovered (Chen et al., 2009; James et al., 2012; Waaler et al.,
2012).
HAP: HYPOXIA-ACTIVATED BIOREDUCTIVE PRODRUGS
The hypoxic microenvironment of solid tumors has attracted
significant attention as target for the development of novel
therapeutics for cancer treatment. A new class of drugs, the
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Chart 2 | Porcupine and Tankyrase inhibitors.
hypoxia activated prodrugs (HAP), has been designed for selec-
tive activation under low oxygen conditions, typical of many solid
tumors. These are prodrugs that are enzymatically converted into
active metabolites (effectors) by endogenous enzymes under the
hypoxic conditions that prevail in tumors (Rauth et al., 1998).
Taking into account the different activation profile, HAP could be
classified into two groups: (1) Class I HAP (such as benzotriazine
N-oxides tirapazamine and SN30000), activated under relatively
mild hypoxia; (2) Class II HAP (such as the nitro compounds
PR-104A or TH-302), activated only under extreme hypoxia (Yin
et al., 2012; Foehrenbacher et al., 2013). Several hypoxia-specific
prodrugs are in various stages of clinical development, although
no registered agents have been used in clinical therapy. Moreover,
the bioreductive compounds are classified in five classes: (1) aro-
matic N-oxides; (2) aliphatic N-oxides; (3) nitro(hetero)cyclic
compounds; (4) quinones; (5) metal complexes.
The N-oxide tirapazamine (TPZ, SR4233) (Chart 3) has been
the most extensively evaluated compound in the clinic to date.
TPZ exhibited up to 300-fold higher toxicity under anoxic condi-
tions than aerobic conditions in vitro (Zeman et al., 1986). TPZ
undergoes one-electron reduction to generate the corresponding
radical able to produce DNA breaks and lesions (Shinde et al.,
2010). Although TPZ has been evaluated in a number of phase II
clinical trials (Marcu and Olver, 2006), the results have not been
translated into increased efficacy over conventional treatment in
phase III clinical trials (Rischin et al., 2010). SN30000 (Chart 3)
is a TPZ analog with improved pharmacokinetic properties and
is presently scheduled to enter phase I clinical trials (Hicks et al.,
2010).
N-oxide banoxantrone (AQ4N) (Chart 3) is metabolized
under hypoxia giving a high affinity DNA intercalating agent,
AQ4, that inhibits topoisomerase II (Patterson et al., 1994).
In preclinical studies, AQ4N, combined with radio- or chemo-
therapy, demonstrated significant increasing activity (Patterson
et al., 2000).
PR-104 (Chart 3), currently in phase II clinical trials, is
a water-soluble phosphate ester pre-prodrug that rapidly is
hydrolyzed in vivo to the prodrug PR-104A, a dinitroben-
zamide mustard that is reduced to p-hydroxylamine and p-
amine metabolites by various oxidoreductases (Singleton et al.,
2009). Another promising compound, TH-302 (Chart 3), is a
2-nitroimidazole-based nitrogen mustard prodrug. The reduc-
tion in hypoxic cells to 2-nitroimidazole and the subsequent
bromoisophosphoramide mustard affects DNA repair pathways
(Meng et al., 2012). TH-302, in combination with chemotherapy,
is currently in phase II and III clinical trials.
Quinone compounds (porfiromycin, RH1, and apaziquone
EO9) (Chart 3) show greater selectivity toward hypoxic cells
where their activation under hypoxia is carried out by one-
electron reductases (Saunders et al., 2000; Phillips et al., 2013;
Guise et al., 2014). Finally, although metal complexes could
be potentially used as hypoxia-selective agents, none have been
developed for clinical use so far.
MISCELLANEOUS
Several molecules, with unrelated chemical structures, are active
toward CSCs. Among these, the antihelmintic niclosamide
(Chart 4) selectively targets ovarian CSCs, and its effect is asso-
ciated with the inhibition of metabolic pathways related to
redox regulation (Yo et al., 2012). Metformin (Chart 4), an anti-
diabetic drug, selectively targets CSCs in multiple types of cancer
including prostate, lung and breast (Hirsch et al., 2009; Shank
et al., 2012) and, in combination with chemotherapeutic agents
(such as doxorubicin, paclitaxel, and carboplatinum) inhibits
tumor growth (Gotlieb et al., 2008). This drug also displays
an anti-proliferative and pro-apoptotic effects on ovarian CSCs
in vitro (Yasmeen et al., 2011). Retinoids, in co-administration
with cis-platinum, affect ovarian CSCs, whereas carboplatinum
alone is not active (Whitworth et al., 2012). Ericalyxin B, a
diterpenoid isolated from Isodon eriocalyx displaying antitumor
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effects via multiple pathways, and 3-Bromopiruvate target ovar-
ian CSCs inducing cell death (Leizer et al., 2011; Wintzell et al.,
2012). Dactinomycin and Plicamycin, two FDA-approved CSCs-
inhibitory compounds, are used in the treatment of several can-
cers including gestational trophoblastic neoplasia, Wilms’ tumor,
testicular cancer and hypercalcemia associated with advanced
malignancy (Kennedy, 1970; Perlia et al., 1970; Lewis et al., 1972;
Frei, 1974; Fraschini et al., 2005; Lee et al., 2006). Disulfiram
(Chart 4), used in alcoholism treatment, is able to reduce cell
growth and self-renewal of glioblastoma stem cells resistant to
temozolomide in vitro by activating apoptotic pathways that
modulate Bcl-2 family (Liu et al., 2012). DECA-14 (Chart 4),
an analog of dequalinium (DECA-10), an antimicrobial agent
and Rapamycin were identified as neuroblastoma (NB) TIC-
selective agents. Both compounds induce CSCs death in vitro,
reduce NB xenograft tumor weight in vivo and decrease self-
renewal in treated tumors (Smith et al., 2010). Furthermore,
NV-128 (Chart 4), an isoflavone derivative, induces cell death
in chemoresistant CSCs population by inhibiting mitochon-
drial function and activating cell death pathways (Alvero et al.,
2011).
CSC AND MDR: REPOSITIONING STRATEGY
The failure of cancer therapy is often due to tumor recurrence
after chemotherapy because in several cancers a residual pool of
CSCs remains (Dean et al., 2005). TICs that survive after ther-
apy evolve in a population of chemoresistant cells able to sustain
the growth of a more aggressive tumor. Among all the protec-
tive mechanisms for CSCs, ABC proteins overexpression is one
of the mostly reported (An and Ongkeko, 2009; Calcagno et al.,
2010; Fuchs et al., 2010; Clevers, 2011; Moitra et al., 2011; Pietras,
2011). There are two models useful to explain the connection
between MDR and CSCs: (i) the original MDR model and (ii)
the acquired MDR model (Holohan et al., 2013). The first model
proposes that, after exposure to the chemotherapeutic agent, only
CSCs expressing ABC transporters repopulate the tumor. The sec-
ond suggests that, after chemotherapy, only CSCs survive and this
population of survival cells, after mutations, originates new and
more aggressive drug-resistant cell phenotypes (Holohan et al.,
2013). The combination of CSCs targeting agents with novel or
conventional cytotoxic drugs could lead to a potentiated effect.
Flavonoids, a large family of polyphenolic molecules, modulate
MDR transporters and inhibit CSCs growth (Colabufo et al.,
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2008c). Flavonoids anticancer properties are due to their antim-
itotic activity and to the inhibition of several enzymes. Recently,
it has been suggested that flavonoids inhibit the function of ABC
transporters such as P-gp, MRPs, and BCRP. Structural require-
ments for the interaction with these pumps are hydrophobic
character and planarity. Flavonoids show low toxicity but, in
the meantime, display a broad spectrum of biological activities
(Colabufo et al., 2008c). Moreover, several studies have pointed
out that flavonoids are able to affect CSCs. Luteolin, Casticin
and 8-Bromo-7-methoxychrysin (BrMC) are active on glioma
stem-like cells (Feng et al., 2012). BrMC is active on hepatocel-
lular carcinoma (Hep-G2 cell line) where it induces apoptotic cell
death by involving ROS products (Yang et al., 2010). LY294002,
a PI3K specific inhibitor, blocks osteosarcoma CSCs cell cycle
(G0/G1) in a dose-dependent manner inducing apoptosis by pre-
venting phosphorylation of PKB/Akt via PI3K phosphorylation
inhibition. Several studies show that this compound also inhibits
BCRP, P-gp, and MRP1 highly expressed in stem cells. LY294002
reverses MDR in CSCs overexpressing BCRP by internalizing this
pump (Imai et al., 2012). LY294002 competitively inhibits MRP1-
mediated doxorubicin efflux in drug-resistant HT29RDB colon
carcinoma cells. Sensitization was not restricted to doxorubicin,
but it was also observed in cells treated with cisplatin, topote-
can, and mitoxantron (Abdul-Ghani et al., 2006). Moreoever,
LY294002 antagonizes transport activity of P-gp by reducing the
degree of vincristine resistance in L1210/VCR mouse leukemic
cell lines in a concentration-dependent manner (Barancík et al.,
2006). However, the simultaneous inhibition of several cellular
signaling pathways, transporters and channels may cause severe
side effects.
Salinomycin, a polyether ionophore antibiotic isolated from
Streptomyces albus, is able to affect CSCs in gastric cancer, lung
adenocarcinoma, osteosarcoma, colorectal cancer, squamous cell
carcinoma (SCC) and prostate by interfering with ABC trans-
porters and CSC crucial pathways (Dong et al., 2011). The com-
bination of salinomycin and the antibody for the anti-human
epidermal growth factor receptor 2 (anti-HER2), trastuzumab,
was found more efficacious than trastuzumab single-treatment in
MCF-7-derived breast CSCs and HER2-expressing breast cancer
cells. In colorectal cancer and in SCC, salinomycin, but not oxali-
platin or cisplatin, is able to reduce the portion of CSCs (Basu
et al., 2011; Dong et al., 2011; Tang et al., 2011; Wang, 2011;
Zhi et al., 2011; Ketola et al., 2012; Oak et al., 2012). Moreover,
salinomycin is active toward human AML CSCs, because it over-
comes ABC transporter-mediated MDR and apoptosis resistance
and inhibits P-gp/MDR1 in different cancer cells (Fuchs et al.,
2010; Riccioni et al., 2010).
CONCLUSIONS AND PERSPECTIVES
Although several items about CSCs theory remain open, there is
a large evidence demonstrating that CSCs are essential to initi-
ate and maintain tumors. CSCs are involved in tumor re-growth
and are resistant to conventional anti-cancer therapy because of
several mechanisms. Among them, the overexpression of ABC
transporters in CSCs membranes represents a novel target for
eradicating tumor relapse. To date, several strategies have been
employed to isolate, target CSCs and circumvent MDR: (i) the
development of sensitive biomarkers and targeted-aptamers; (ii)
the evaluation of CSCs microenvironment; (iii) the study of the
genes and pathways involved in CSCs regulation; (iv) evaluation
of known and new molecules able to affect both TIC populations
and ABC transporters. Therefore, the next challenge in this field
may be amultimodal strategy, an approach in which specific CSCs
targeting drugs exert simultaneously the ability to circumvent
tumor drug resistance (ABC transporters modulation) and cyto-
toxic activity toward CSCs and the corresponding differentiated
tumor cells. The efficacy of this suggested multimodal strategy
will be probed by using several scaffolds active toward MDR
pumps on CSCs isolated by tumor specimens.
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